Vaccination of hormone‐refractory prostate cancer patients with peptide cocktail‐loaded dendritic cells: Results of a phase I clinical trial

Abstract

The described protocol represents a safe and feasible concept for the induction of clinical and immunological responses. The application of a peptide cocktail-derived from different antigens as a novel treatment modality is supposed to allow for the genetic and biologic heterogeneity of PCa.